scholarly journals Re-Arterialized Rat Partial Liver Transplantation with an in vivo Vessel-Oriented 70% Hepatectomy

10.3791/56392 ◽  
2018 ◽  
Author(s):  
Xuehai Chen ◽  
Rong Yu ◽  
Ziqiang Xu ◽  
Yan Zhang ◽  
Chengyang Liu ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Partial Liver Transplantation

scholarly journals Research Status of Mesenchymal Stem Cells in Liver Transplantation

2019 ◽  
Vol 28 (12) ◽  
pp. 1490-1506 ◽  
Author(s):  
Yu You ◽  
Di-guang Wen ◽  
Jian-ping Gong ◽  
Zuo-jin Liu
Keyword(s):  
Stem Cells ◽  
Liver Transplantation ◽  
Clinical Trials ◽  
Mesenchymal Stem Cells ◽  
In Vivo Studies ◽  
Cell Contact ◽  
Clinical Effects ◽  
Clinical Safety

Liver transplantation has been deemed the best choice for end-stage liver disease patients but immune rejection after surgery is still a serious problem. Patients have to take immunosuppressive drugs for a long time after liver transplantation, and this often leads to many side effects. Mesenchymal stem cells (MSCs) gradually became of interest to researchers because of their powerful immunomodulatory effects. In the past, a large number of in vitro and in vivo studies have demonstrated the great potential of MSCs for participation in posttransplant immunomodulation. In addition, MSCs also have properties that may potentially benefit patients undergoing liver transplantation. This article aims to provide an overview of the current understanding of the immunomodulation achieved by the application of MSCs in liver transplantation, to discuss the problems that may be encountered when using MSCs in clinical practice, and to describe some of the underlying capabilities of MSCs in liver transplantation. Cell–cell contact, soluble molecules, and exosomes have been suggested to be critical approaches to MSCs’ immunoregulation in vitro; however, the exact mechanism, especially in vivo, is still unclear. In recent years, the clinical safety of MSCs has been proven by a series of clinical trials. The obstacles to the clinical application of MSCs are decreasing, but large sample clinical trials involving MSCs are still needed to further study their clinical effects.

Impaired volume regeneration of split livers with partial venous disruption: a latent problem in partial liver transplantation

2002 ◽  
Vol 73 (5) ◽  
pp. 765-769 ◽  
Author(s):  
Atsushi Maema ◽  
Hiroshi Imamura ◽  
Tadatoshi Takayama ◽  
Keiji Sano ◽  
Ai-Min Hui ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Partial Liver Transplantation

Living-related partial liver transplantation for decompensated hepatitis B without reactivation of hepatitis B in the following 30 months

2001 ◽  
Vol 36 (9) ◽  
pp. 637-642 ◽  
Author(s):  
Kiyoshi Hasegawa ◽  
Etsuko Hashimoto ◽  
Naoko Kanai ◽  
Miho Ogawa ◽  
Takuma Naritomi ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Hepatitis B ◽  
Partial Liver Transplantation ◽  
Living Related

scholarly journals Predictors of Survival After In Vivo Split Liver Transplantation

2000 ◽  
Vol 232 (3) ◽  
pp. 312-323 ◽  
Author(s):  
Rafik M. Ghobrial ◽  
Hasan Yersiz ◽  
Douglas G. Farmer ◽  
Farin Amersi ◽  
John Goss ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Split Liver Transplantation ◽  
Split Liver

scholarly journals The immunoregulation of mesenchymal stem cells plays a critical role in improving the prognosis of liver transplantation

2019 ◽  
Vol 17 (1) ◽  
Author(s):  
Chenxia Hu ◽  
Lanjuan Li
Keyword(s):  
Liver Transplantation ◽  
Natural Killer ◽  
Immune Cells ◽  
Adaptive Systems ◽  
Critical Role ◽  
Arterial System ◽  
Cell Mediated Immunity ◽  
Adaptive Immune Cells

AbstractThe liver is supplied by a dual blood supply, including the portal venous system and the hepatic arterial system; thus, the liver organ is exposed to multiple gut microbial products, metabolic products, and toxins; is sensitive to extraneous pathogens; and can develop liver failure, liver cirrhosis and hepatocellular carcinoma (HCC) after short-term or long-term injury. Although liver transplantation (LT) serves as the only effective treatment for patients with end-stage liver diseases, it is not very popular because of the complications and low survival rates. Although the liver is generally termed an immune and tolerogenic organ with adaptive systems consisting of humoral immunity and cell-mediated immunity, a high rejection rate is still the main complication in patients with LT. Growing evidence has shown that mesenchymal stromal cell (MSC) transplantation could serve as an effective immunomodulatory strategy to induce tolerance in various immune-related disorders. MSCs are reported to inhibit the immune response from innate immune cells, including macrophages, dendritic cells (DCs), natural killer cells (NK cells), and natural killer T (NKT) cells, and that from adaptive immune cells, including T cells, B cells and other liver-specific immune cells, for the generation of a tolerogenic microenvironment. In this review, we summarized the relationship between LT and immunoregulation, and we focused on how to improve the effects of MSC transplantation to improve the prognosis of LT. Only after exhaustive clarification of the potential immunoregulatory mechanisms of MSCs in vitro and in vivo can we implement MSC protocols in routine clinical practice to improve LT outcome.

Collaboration with microsurgery prevents arterial complications and provides superior success in partial liver transplantation

Microsurgery ◽  
2006 ◽  
Vol 26 (7) ◽  
pp. 490-497 ◽  
Author(s):  
Betul Gozel Ulusal ◽  
Ming-Huei Cheng ◽  
Ali Engin Ulusal ◽  
Wei-Chen Lee ◽  
Fu-Chan Wei
Keyword(s):  
Liver Transplantation ◽  
Partial Liver Transplantation ◽  
Arterial Complications
Sign in / Sign up

Export Citation Format

Share Document